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Introduction
============

Head and neck cancer is common among the United States Veteran population and is increasingly being managed with organ preservation strategies \[[@REF1]\]. Radiotherapy (RT) with or without concurrent systemic therapy (CST) can result in a long-term cure in patients with a variety of primary sites and stages, but late toxicity such as dysphagia and swallowing dysfunction can be debilitating and permanent and lead to dependence on enteral feeding \[[@REF2]-[@REF6]\]. Late percutaneous endoscopic gastrostomy (PEG) tube dependence has been associated with a variety of clinical and tumor factors, but the association between late swallowing dysfunction and overall survival (OS) has not been explored \[[@REF7]-[@REF9]\]. The hypothesis of this retrospective study is that late swallowing dysfunction necessitating PEG support is associated with worse OS in patients with locally advanced head and neck cancer patients cured with definitive RT and CST.

Materials and methods
=====================

Patient and treatment characteristics

The study population included veteran patients referred for a formal swallowing evaluation between 2008 and 2017 to the Speech Pathology Clinic at the Bay Pines VA Healthcare System, C.W. Bill Young Veterans Affairs (VA) Medical Center, after completion of definitive RT and CST for locally advanced head and neck cancer. Informed consent was waived for this Institutional Review Board approved retrospective review of patient medical records.

Patients were included for analysis if they met the following criteria: biopsy-proven squamous cell carcinoma of the head and neck; American Joint Committee on Cancer (AJCC) 7th Edition stage III, IVA, or IVB disease; minimum follow-up of 90 days after completing RT; at least one post-RT modified barium swallow study; no evidence of disease at the time of the last follow-up; and treated with definitive RT and CST. Patients were excluded from analysis if they had undergone major head and neck surgery including definitive surgical resection or neck dissection, had evidence of local, regional, or distant recurrence of head and neck cancer, or had non-squamous cell carcinoma histology.

CPRS records were reviewed to determine disease status at the last follow-up, PEG dependency, overall length of follow-up, and survival status. Patients were assigned either PEG-dependent or PEG-independent status at the time of the last follow-up.

Statistical analysis

Statistical analyses were performed using Statistical Product and Service Solutions (SPSS) Version 24.0 (IBM Corp., Chicago, Illinois, USA) to assess the relationship between clinical, tumor, and treatment characteristics, and PEG dependence and survival. Estimates of OS were calculated using the Kaplan-Meier method, and differences between groups were estimated with the log-rank test. OS was defined as years from the time of diagnosis to death or the last follow-up. Univariate and multivariate Cox-proportional hazards model was used to evaluate the impact of various clinical factors on OS. The chi-square test was used to assess any differences between PEG-dependent and PEG-independent groups at baseline. Statistical significance was defined as p\<0.05.

Results
=======

Patient cohort

Overall, 62 patients were included in the final study population. Distribution of patient demographics, tumor primary site, and staging is available in Table [1](#TAB1){ref-type="table"}.

###### Patient characteristics, tumor primary site, and staging

\*Continuous variables are displayed as median (range)

RT, radiotherapy; MBS, modified barium swallow; AJCC, American Joint Committee on Cancer; IMRT, intensity-modulated radiotherapy; 3D, three-dimensional; PEG, percutaneous endoscopic gastrostomy

  --------------------------------------- -------------------
  Characteristic (n=62)                   Frequency (%)
  Population characteristics              
  Median age (years)\*                    64 (50--94)
  Gender                                   
       Male                               60 (96.8)
  Smoking status                           
       Current/former                     56 (90.3)
  History of stroke                        
       No                                 58 (93.5)
  Median time from RT to MBS (months)\*   9.9 (0.2--162)
  Tumor primary site                      
  Oropharynx                              31 (50.0)
       Base of tongue                     16 (25.8)
       Tonsil                             12 (19.4)
       Posterior wall                     2 (3.2)
       Soft palate                        1 (1.6)
  Larynx                                  17 (27.4)
       Supraglottic                       10 (16.1)
       Glottic                            7 (11.3)
  Hypopharynx                             7 (11.3)
  Unknown primary                         6 (9.7)
  Nasopharynx                             1 (1.6)
  Staging                                 
  AJCC 7th edition stage                   
       III                                15 (24.2)
       IVA                                45 (72.6)
       IVB                                2 (3.2)
  T stage                                  
       Tx                                 6 (9.7)
       T1                                 7 (11.3)
       T2                                 19 (30.6)
       T3                                 20 (32.3)
       T4a                                9 (14.5)
       T4b                                0 (0.0)
       Unknown                            1 (1.6)
  N stage                                  
       N0                                 8 (12.9)
       N1                                 13 (21.0)
       N2a                                2 (3.2)
       N2b                                21 (33.9)
       N2c                                15 (24.2)
       N3                                 2 (3.2)
       Unknown                            1 (1.6)
  Treatment characteristics               
  Radiation era                            
        2012 or earlier                   30 (48.4)
        2013 or later                     32 (51.6)
  Chemotherapy regiment                    
       Cisplatin                          38 (61.3)
       Other                              10 (16.1)
       Cetuximab                          7 (11.2)
       Carboplatin                        4 (6.5)
       Unknown                            3 (4.8)
  Median radiation dose (cGy)\*           7000 (6800--7440)
  Radiation schedule                       
       Conventional                       41 (66.1)
       Accelerated/hyperfractionated      2 (3.2)
       Unknown                            19 (30.6)
  Radiation modality                       
       IMRT                               36 (58.1)
       3D conformal                       4 (6.5)
       Unknown                            22 (35.5)
  Received hyperbaric oxygen               
       Yes                                5 (8.1)
  Prophylactic PEG                         
       Yes                                51 (82.2)
  --------------------------------------- -------------------

The median patient age at the time of treatment was 64 years (range: 50-94 years), with 96.8% of the cohort being males. Most patients were stage IVA at diagnosis (72.6%, n=45), had oropharyngeal tumors (50.0%, n=31), and were treated with platinum-based CST (77.4%, n=48). At the time of analysis, 46 (74.2%) patients were considered PEG dependent and 16 (25.8%) were determined to be PEG independent. Patient, tumor, and treatment characteristics were not significantly different between the PEG- dependent and PEG-independent groups (Table [2](#TAB2){ref-type="table"}).

###### Distribution of patient, tumor, and treatment characteristics in PEG-dependent and PEG-independent patients

PEG, percutaneous endoscopic gastrostomy; HBO, hyperbaric oxygen; 3D, three-dimensional; IMRT, intensity-modulated radiotherapy

  -------------------------- ------------------------ -------------------------- ---------
  Characteristic             PEG dependent (n = 16)   PEG independent (n = 46)   p-Value
  Stage                                                                          0.555
       III                   3                        12                          
       IVA or IVB            13                       34                          
  T stage                                                                        0.143
       T3 or T4              10                       19                          
       T1 or T2              6                        27                          
  N stage                                                                        0.367
       N2c or N3             3                        14                          
       N2b or lower          13                       32                          
  Radiation era                                                                  0.881
       2012 or earlier       8                        22                          
       2013 or later         8                        24                          
  Age at treatment                                                               0.101
       71 years or older     5                        6                           
       70 years or under     11                       40                          
  Type of systemic therapy                                                       0.722
       Cisplatin             10                       31                          
       Non-cisplatin         6                        15                          
  Hyperbaric oxygen                                                              0.068
       Received HBO          3                        2                           
       Did not receive HBO   13                       44                          
  Prophylactic PEG                                                               0.617
       Yes                   13                       38                          
       No                    3                        6                           
       Unknown               0                        2                           
  Radiation modality                                                             0.301
       3D conformal          2                        2                           
       IMRT                  7                        29                          
       Unknown               7                        15                          
  Tumor primary site                                                             0.477
       Larynx/hypopharynx    5                        19                          
       Other                 11                       27                          
  Tobacco use                                                                    0.590
       Yes/former            15                       41                          
       No                    1                        5                           
  -------------------------- ------------------------ -------------------------- ---------

Factors influencing overall survival

The following clinical information was collected and analyzed by univariate analysis for association with OS: PEG dependence, overall stage, T stage, N stage, radiation era, age at treatment, type of CST, use of hyperbaric oxygen, prophylactic PEG use, tumor primary site, and tobacco use (Table [3](#TAB3){ref-type="table"}).

###### Univariate analysis of patient and treatment characteristics associated with OS

CI, confidence interval; OS, overall survival; PEG, percutaneous endoscopic gastrostomy; HBO, hyperbaric oxygen

  -------------------------------------- ----------------------- --------------------- ---------
  Factor                                 Hazard ratio (95% CI)   Five-year OS (%)      p-Value
  PEG dependence                                                                        
       PEG dependent                     2.59 (1.11--5.99)       64.3                  0.028
       PEG independent (reference)                               86.1                   
  Stage                                                                                 
       III                               1.46 (0.25--1.91)       75.8                  0.468
       IVA or IVB (reference)                                    83.0                   
  T stage                                                                               
       T3 or T4                          1.05 (0.40--2.23)       88.1                  0.904
       T1 or T2 (reference)                                      74.0                   
  N stage                                                                               
       N2c or N3                         0.65 (0.62--3.82)       73.7                  0.353
       N2b or lower (reference)                                  83.9                   
  Radiation era                                                                         
       2012 or earlier                   2.70 (0.09--1.53)       90.0 (four-year OS)   0.155
       2013 or later (reference)                                 80.2 (four-year OS)    
  Age at treatment                                                                      
       71 years or older                 2.57 (0.99--6.65)       72.7                  0.052
       70 years or under (reference)                             82.9                   
  Type of systemic therapy                                                              
       Cisplatin                         0.87 (0.47--2.81)       82.7                  0.752
       Non-cisplatin (reference)                                 75.2                   
  Hyperbaric oxygen                                                                     
       Received HBO                      0.68 (0.49--4.50)       60.0                  0.486
       Did not receive HBO (reference)                           83.4                   
  Prophylactic PEG                                                                      
       Yes                               0.52 (0.63--5.85)       79.4                  0.248
       No (reference)                                            87.5                   
  Primary site                                                                          
       Larynx/hypopharynx                1.16 (0.35--2.09)       75.8                  0.740
       Other (reference)                                         83.9                   
  Tobacco use                                                                           
       Yes/former                        0.78 (0.30--5.62)       80.8                  0.734
       No (reference)                                            80.0                   
  -------------------------------------- ----------------------- --------------------- ---------

Detailed RT dosimetric information was available for only 25 of the 62 patients; therefore, information on radiation modality and dose was not included in the univariate and multivariate analyses.

On univariate analysis, PEG-dependent patients (hazard ratio \[HR\]: 2.59; 95% confidence interval \[CI\]: 1.11-5.99; p=0.028) and patients aged 71 years or older at treatment (HR: 2.57; 95% CI: 0.99-6.65; p=0.052) had worse OS outcomes. No other factors were associated with OS on univariate analysis. On multivariate analysis, the following were recognized to have worse OS: PEG dependency (HR: 4.25; 95% CI: 1.33-13.62; p=0.015), advanced N stage (HR: 4.74; 95% CI: 1.17-19.26; p=0.032), and older age at treatment (HR: 4.37; 95% CI: 1.21-15.84; p=0.014) (Table [4](#TAB4){ref-type="table"}).

###### Multivariable Analysis of patient and treatment characteristics associated with survival

CI, confidence interval; PEG, percutaneous endoscopic gastrostomy; HBO, hyperbaric oxygen

  ------------------------ ----------------------- ---------
  Factor                   Hazard ratio (95% CI)   p-Value
  PEG dependence           4.25 (1.33--13.62)      0.015
  Lower overall stage      1.06 (0.21--5.45)       0.945
  Higher T stage           1.16 (0.44--3.04)       0.763
  Higher N stage           4.74 (1.17--19.26)      0.030
  Earlier radiation era    0.36 (0.07--1.84)       0.220
  Older age at treatment   4.37 (1.21--15.84)      0.025
  Cisplatin therapy        1.20 (0.44--3.29)       0.719
  HBO use                  1.18 (0.31--4.48)       0.808
  Prophylactic PEG         3.09 (0.75--12.78)      0.119
  Primary tumor site       1.10 (0.29--4.16)       0.884
  Tobacco use              0.53 (0.07--3.93)       0.530
  ------------------------ ----------------------- ---------

The median follow-up after the completion of definitive RT and CST was 48 months (range: 7.6-235 months). There was an observed worsening in OS for PEG-dependent patients (median of 6.54 years \[95% CI: 3.62 - NA\] with PEG dependence vs. median of 9.39 years \[95% CI: 7.90 - NA\] with PEG independence). The five-year OS was 64.3% in the PEG-dependent group and 86.1% in the PEG-independent group (p=0.022) (Figure [1](#FIG1){ref-type="fig"}). Older age at treatment was also associated with poorer OS (p=0.044, not shown).

![The Kaplan-Meier survival curve showing OS for PEG-dependent (dashed line) and PEG-independent (solid line) patients, p=0.022 (log-rank test)\
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Discussion
==========

In a cohort of patients with non-resected stage III or IVA/B head and neck squamous cell carcinoma definitively cured with RT and CST in the C.W. Bill Young VA Medical Center, we found that PEG dependency was significantly associated with worse OS compared with PEG-independence. Therefore, long-term RT and CST toxicities leading to late feeding tube dependence may have substantial survival implications, and the provider decision for PEG placement should be weighed heavily. Similarly, in accordance with the NCCN (National Comprehensive Cancer Network) guidelines and other literature, prophylactic PEG tubes and enteral feeding should only be employed when unequivocally necessitated \[[@REF10],[@REF11]\]. The risks of potential PEG tube dependence must be weighed against the nutritional benefits. By the best of our knowledge, this is the first report describing survival outcomes in a PEG-dependent cohort in comparison with their PEG-independent counterparts.

It is well known that organ-preserving strategies used to cure locally advanced head and neck carcinoma may induce significant acute and long-term side effects. Acute toxicities such as skin toxicity or mucositis often temporarily disrupt swallowing function during treatment but are often transient in nature. In contrast, late effects including neuropathy and fibrosis of oropharyngeal musculature may result in permanently disabling dysphagia, necessitating enteral support to reduce the risk of life-threatening pneumonia and support nutritional habits \[[@REF12]-[@REF14]\]. One smaller study found that as a result of late toxicity dysphagia, 66% of the cohort was gastrostomy-dependent \[[@REF15]\]. Known predictors of PEG tube placement include patient advanced age, primary tumor site, smoking status, higher T and N stages, body mass index of less than 25, accelerated irradiation fractionation, and use of high-dose chemotherapy \[[@REF7],[@REF9]\].

While feeding tube dependency is relatively common, few studies have explored the relationship between enteral support and survival \[[@REF4],[@REF5],[@REF16],[@REF17]\]. At the time of the last follow-up, 16 (26%) patients of our cohort were found to be feeding tube dependent. In the GORTEC 99-02 trial comparing fractionation schedules for locally advanced head and neck carcinoma, rates of feeding tube placement varied, with 60% in the conventionally fractionated group, 64% in the hyperfractionated, and 70% in the very accelerated RT patients. At the five-year follow-up, 13% of conventionally fractionated patients were feeding tube dependent versus 25% of the very accelerated RT group (p=0.027) \[[@REF4]\]. Pooled analyses have also demonstrated a feeding tube dependency rate of 10.3% in a locally advanced cohort \[[@REF5]\]. A small retrospective study evaluated the timing of PEG placement and OS and showed that prophylactic PEG use had worse outcomes (HR: 11.62; 95% CI: 1.77-76.47; p=0.011) \[[@REF17]\]. However, this study did not evaluate long-term PEG dependency and may thus explain our study results that prophylactic PEG use did not result in worse OS, rather long-term PEG dependency appears to be a key factor in driving survival.

Reducing post-chemoradiation toxicity may improve OS due to decreased PEG tube dependence. The mean dose to swallowing organs significantly predicts long-term dysphagia; ergo, it is possible that intensity-modulated RT (IMRT) may lead to less dysphagia as the technique can spare the pharyngeal constrictor muscles and supraglottic larynx \[[@REF18],[@REF19]\]. Although not yet clinically validated, the introduction of functional swallowing units (FSUs), defined by hyolaryngeal elevation, tongue base retraction, and tongue motion, is certainly promising. Using these contouring guidelines to mark the delineation of FSUs may reduce toxicity, leading to better outcomes \[[@REF20],[@REF21]\]. A new randomized control trial is planned to more definitively explore the role of IMRT in reducing dysphagia \[[@REF22]\]. Regarding our study, more than half of our cohort received IMRT-based therapy. However, due to unavailable data for 35.5% of patients, radiation modality was not included in our survival analysis. Of the 36 IMRT patients, only 7 (19.4%) were PEG dependent at the last follow-up. Future research may show that patients receiving IMRT have better outcomes due to less PEG dependency.

Similarly, toxicity mitigation through non-treatment altering programs offers promise in the reduction of late dysphagia. Prophylactic swallowing programs have frequently been investigated as an attempt to reduce post-radiation fibrosis and improve dysphagia-related outcomes \[[@REF23]-[@REF26]\]. Carnaby-Mann et al. demonstrated that twice daily swallowing musculature exercises resulted in significantly less dysphagia compared with usual care and sham exercises, whereas van der Molen et al. showed that preventative exercises resulted in less feeding tube dependency compared with other institutional trials \[[@REF23],[@REF25]\]. Overall, these studies concluded that swallowing programs have a beneficial reduction in acute swallowing issues. However, long-term outcomes and if these programs lead to a reduction in PEG dependence or OS are still unknown. On the other hand, additional retrospective studies have shown that prophylactic PEG tubes often lead to increased esophageal strictures and increased PEG dependence, and do not impact treatment times \[[@REF10],[@REF24],[@REF27]\]. These previous studies suggest that avoidance of prophylactic PEG tubes may improve outcomes, which is reinforced by our findings that PEG dependence is associated with worse OS.

Recently, efforts to de-intensify treatment to reduce significant toxicity while delivering similar efficacy have been explored. A recent analysis of VA patients receiving definitive concurrent chemoradiation for stage III-IVB unresectable head and neck cancer showed that low-dose cisplatin compared with high-dose cisplatin resulted in no change in survival with simultaneous toxicity reduction \[[@REF28]\]. Similarly, in an early de-intensification trial, Chera et al. showed that de-intensification of chemoradiotherapy (e.g., with 60 Gy of IMRT and ipsilateral RT for tonsil cancers) resulted in favorable outcomes \[[@REF6]\]. In the evolving era of immunotherapy, we anticipate the incorporation of immunotherapy into the standard of care for locally advanced and advanced head and neck carcinomas. We eagerly anticipate the results of two clinical trials evaluating the role of pembrolizumab in locally advanced head and neck malignancies (NCT03040999) and in patients who are cisplatin-ineligible due to significant toxicity (NCT02609503).

We acknowledge that there are limitations of a small cohort-based, retrospective analysis. First, our study did not have the means to assess human papillomavirus (HPV) or p16 status. These factors offer a prognostic benefit to patients with squamous cancers of the head and neck and can significantly alter outcomes \[[@REF29]\]. Specific staging for HPV positive oropharyngeal cancer has been adopted in the AJCC 8th edition staging guidelines; therefore, a more careful stratification of non-HPV or HPV-related cancers in patients with PEG dependence must be assessed. Due to the nature of our study, we are unaware of the indications for original PEG tube placement or for the nature of speech pathology referral. Protocols for PEG placement often vary at clinical institutions, and the uncertainty as to why each PEG tube was used offers confounding factors in our study. Also, our study does not include data regarding nasogastric tubes, which are sometimes used as an alternative to PEG tubes. Finally, we acknowledge that our survival outcomes are far superior to landmark and other similar trials. The five-year OS rates reported in these trials range from approximately 20 to 45%, depending on the primary site \[[@REF28],[@REF30]\]. The actuarial five-year OS for this patient cohort was higher (84.1% for PEG-independent patients and 64.3% for PEG-dependent patients) because only patients who had no evidence of disease at the time of the last follow-up were included in the analysis. The study was designed in this manner to decrease confounding on OS and further strengthen the relationship between late swallowing dysfunction, PEG dependency, and OS.

In the future, we hope to expand our analyses from our single institution. We aim to use the VA Corporate Data Warehouse (CDW) to achieve this goal. The CDW pools medical records from VA centers and other government databases across the nation to afford the opportunity for large-scale data mining and allow access to multicenter informatics. We anticipate that expanding our study cohort may offer more insight into the details that explain our findings.

Conclusions
===========

In conclusion, our data suggest that PEG dependence is significantly associated with worse OS, further supporting the fact that minimizing RT and CST side effects drastically improves patient care. Providers should carefully consider the use of enteral feeding and recognize the potential risks associated with late feeding tube dependency.
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